Neosine Forte (Inosine Pranobex)

Neosine Forte (Inosine Pranobex) is employed as an antiviral immunomodulator to enhance host defenses across several viral disease categories.

• Herpes simplex infections: shortens lesion healing time and reduces viral shedding.
• Human papillomavirus (HPV) infections: supports clearance of cutaneous and mucosal lesions.
• Influenza: mitigates symptom severity and may shorten disease duration.
• Immunodeficiency conditions: augments cellular immunity to help control opportunistic viral infections.

• Inosine Pranobex exerts its antiviral immunomodulatory effect by stimulating the proliferation and activity of T‑lymphocytes and natural killer (NK) cells. It enhances the production of interleukin‑2 and interferon‑γ, thereby promoting a Th1‑biased immune response. The heightened cellular immunity interferes with viral replication and facilitates clearance of infected cells across a broad spectrum of viruses. Additionally, it may modulate cytokine release, contributing to a balanced antiviral environment.

Inosine Pranobex is generally well tolerated, but several adverse reactions have been reported.

Common Side Effects

• Nausea: mild to moderate stomach upset that may resolve without treatment.
• Headache: transient cranial discomfort, often relieved with simple analgesics.
• Dizziness: occasional light‑headedness, especially when standing quickly.
• Rash: mild skin erythema or pruritus that typically subsides after discontinuation.

Serious or Rare Side Effects

• Anaphylaxis: severe allergic reaction characterized by hives, swelling, respiratory distress and hypotension; requires immediate medical attention.
• Hepatotoxicity: elevated liver enzymes or clinical hepatitis, potentially leading to jaundice; monitor liver function during therapy.
• Hematologic abnormalities: neutropenia, thrombocytopenia, or anemia that may increase infection or bleeding risk; regular blood counts are advised.
• Severe cutaneous reactions: Stevens‑Johnson syndrome or toxic epidermal necrolysis presenting with extensive skin detachment and mucosal involvement; discontinue drug promptly.

When prescribing Neosine Forte, clinicians should consider several precautionary measures to ensure patient safety.

• Renal impairment: assess kidney function and monitor for accumulation.
• Hepatic dysfunction: evaluate liver enzymes before initiation and during treatment.
• Immunocompromised patients: weigh benefits against potential overstimulation of immune response.
• Pregnancy: use only if clearly indicated after risk‑benefit assessment.
• Concomitant immunosuppressants: monitor for reduced efficacy or enhanced toxicity.
• Store at ambient temperature: keep in original packaging, protect from moisture and light.

Inosine Pranobex may interact with other medicines, altering its efficacy or safety profile.

Major Interactions (Avoid)

• Immunosuppressive agents: concurrent use may diminish the drug’s immunostimulatory effect.
• Live vaccines: co‑administration can reduce vaccine‑induced immunity.
• Anticoagulants: potential for increased bleeding risk due to platelet function changes.

Moderate Interactions (Monitor Closely)

• Corticosteroids: may enhance immunomodulatory activity, requiring clinical observation.
• Antiretroviral therapy: possible pharmacodynamic interaction that could affect viral control.